Nicole L. YatesHua Xin LiaoYouyi FongAllan DeCampNathan A. VandergriftWilliam T. WilliamsS. Munir AlamGuido FerrariZhi Yong YangKelly E. SeatonPhillip W. BermanMichael D. AlpertDavid T. EvansRobert J. O'ConnellDonald FrancisFaruk SinangilCarter LeeSorachai NitayaphanSupachai Rerks-NgarmJaranit KaewkungwalPunnee PitisuttithumJames TartagliaAbraham PinterSusan Zolla-PaznerPeter B. GilbertGary J. NabelNelson L. MichaelJerome H. KimDavid C. MontefioriBarton F. HaynesGeorgia D. TomarasDuke UniversityFred Hutchinson Cancer Research CenterNational Institute of Allergy and Infectious DiseasesUniversity of California, Santa CruzHarvard Medical SchoolArmed Forces Research Institute of Medical Sciences, ThailandGlobal Solutions for Infectious DiseasesThailand Ministry of Public HealthMahidol UniversitySanofi PasteurRutgers New Jersey Medical SchoolNYU School of MedicineWalter Reed Army Institute of ResearchSanofiUniversity of Wisconsin Madison2018-11-092018-11-092014-03-19Science Translational Medicine. Vol.6, No.228 (2014)19466242194662342-s2.0-84899087118https://repository.li.mahidol.ac.th/handle/20.500.14594/34265HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.Mahidol UniversityMedicineArticleSCOPUS10.1126/scitranslmed.3007730